☆ 4.8 Article

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo- controlled, phase 2b trial

LANCET (2022)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020

David J. Gladstone et al.

Summary: The 2020 update of the Canadian Stroke Best Practice Recommendations (CSBPR) for the Secondary Prevention of Stroke includes evidence-based recommendations and expert opinions to guide clinicians in preventing ischemic stroke recurrence through the management of modifiable risk factors. The updated guidelines address various aspects of stroke prevention, including triage, diagnostic testing, lifestyle behaviors, medication therapies, and recommendations for different conditions such as atrial fibrillation and hyperlipidemia. The addition of new recommendations and revised treatment guidelines reflect the evolving evidence in stroke management.

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Medicine, General & Internal

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini et al.

Summary: This study compared the incidence of bleeding in patients with atrial fibrillation between Asundexian and apixaban, showing that Asundexian resulted in lower rates of bleeding compared with standard dosing of apixaban.

LANCET (2022)

Add to Collection

Article Clinical Neurology

Frequency and patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial

Mukul Sharma et al.

Summary: This study aimed to determine the frequency and pattern of brain infarcts in patients with ESUS. The MRI results showed that the majority of ESUS patients had multiple infarcts, even without a prior history of clinical stroke or transient ischemic attack. These findings indicate a significant burden of clinical stroke and covert brain infarction in ESUS patients.

STROKE (2022)

Add to Collection

Article Medicine, General & Internal

Milvexian for the Prevention of Venous Thromboembolism

Jeffrey Weitz et al.

Summary: The study results showed that in knee arthroplasty patients receiving different doses of milvexian treatment, the incidence of venous thromboembolism with twice-daily dosing was significantly lower than the prespecified benchmark of 30%, with a lower risk of bleeding compared to enoxaparin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Hematology

Factor XI as a Target for New Anticoagulants

James C. Fredenburgh et al.

Summary: The article discusses the rationale for developing factor XI inhibitors, identifies the most advanced stage agents, describes the results of completed clinical trials and ongoing trials, highlighting opportunities and challenges for this new generation of anticoagulants.

HAMOSTASEOLOGIE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Factor XI Inhibition to Uncouple Thrombosis From Hemostasis JACC Review Topic of the Week

Charles Hsu et al.

Summary: Hemostasis and thrombosis are closely linked, with factor XI inhibitors potentially providing a safer alternative to current anticoagulants. Clinical studies are ongoing to determine the efficacy of factor XI inhibitors in attenuating thrombosis without disrupting hemostasis.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Hematology

Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case-control study

Huiting Chen et al.

Summary: The study found that factor XI levels were more closely associated with an increased risk of ischemic stroke, while factor X levels were not associated with incident ACS or stroke.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Abelacimab for Prevention of Venous Thromboembolism

Peter Verhamme et al.

Summary: Factor XI plays a significant role in the development of postoperative venous thromboembolism. Inhibition of Factor XI with a single intravenous dose of abelacimab after total knee arthroplasty was effective in preventing venous thromboembolism and had a low risk of bleeding.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Clinical Neurology

2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association

Dawn O. Kleindorfer et al.

Summary: Additional digital content is available in the text.

STROKE (2021)

Add to Collection

Review Clinical Neurology

The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy

Odysseas Kargiotis et al.

Summary: Recent studies have shown the effectiveness of early DAPT for the secondary prevention after minor strokes or TIA, making it a more popular choice of treatment. However, there is still controversy surrounding the duration of DAPT and the individualized selection of patients based on their risk factors for bleeding and potential benefits in preventing future ischemic events.

CURRENT OPINION IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA

Jesse Dawson et al.

Summary: It is strongly recommended to use aspirin and clopidogrel dual antiplatelet therapy for 21 days in patients with non-cardioembolic minor ischemic stroke or high-risk TIA in the past 24 hours, based on high quality evidence. It is weakly recommended to use aspirin and ticagrelor dual antiplatelet therapy for 30 days in patients with non-cardioembolic mild to moderate ischemic stroke or high-risk TIA in the past 24 hours, based on moderate quality evidence.

EUROPEAN STROKE JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes A Secondary Analysis of the COMPASS Trial

Kanjana S. Perera et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty The FOXTROT Randomized Clinical Trial

Jeffrey I. Weitz et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Clinical Neurology

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline The COMPASS MRI Substudy

Mukul Sharma et al.

STROKE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome

Michael Chong et al.

CIRCULATION (2019)

Add to Collection

Article Medicine, General & Internal

Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA

S. Claiborne Johnston et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Clinical Neurology

Genetically Determined FXI (Factor XI) Levels and Risk of Stroke

Dipender Gill et al.

STROKE (2018)

Add to Collection

Article Medicine, General & Internal

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

J. W. Eikelboom et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice

Reut Shnerb Ganor et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Harry R. Bueller et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Clinical Neurology

The Heidelberg Bleeding Classification Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy

Ruediger von Kummer et al.

STROKE (2015)

Add to Collection

Article Hematology

Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women

B. Siegerink et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)

Add to Collection

Article Medicine, General & Internal

Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack

Yongjun Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Hematology

Reduced incidence of ischemic stroke in patients with severe factor XI deficiency

Ophira Salomon et al.

BLOOD (2008)

Add to Collection

Article Medicine, General & Internal

Higher risk of ischaemic stroke associated with factor XI levels in dyslipidaemic patients

A. Santamaria et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)

Add to Collection

Article Hematology

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

S Schulman et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)

Add to Collection

Article Clinical Neurology

Risk factors for TIA and TIA as a risk factor for stroke

RL Sacco

NEUROLOGY (2004)

Add to Collection

Article Medicine, General & Internal

Silent brain infarcts and the risk of dementia and cognitive decline

SE Vermeer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.